BOOK DEMO

The Hidden Costs of Speed in Pharma Manufacturing Expansion

The Hidden Costs of Speed in Pharma Manufacturing Expansion Pharmaceutical companies have approached capital planning in a predictable fashion over the years. They took a long-term view of facility expansions. Forecasting manufacturing demand followed a “standard” pattern. The approval process for capital projects went through deliberate cycles, allowing time to evaluate trade-offs, budgets and portfolio […]

Capex Confidential: Pharma & Biotech

INSIDER PERSPECTIVES FOR CAPITAL INVESTMENT STAKEHOLDERS Regulatory scrutiny. Scientific breakthroughs. Market saturation in once-lucrative therapeutic areas. Few industries experience change at the velocity pharma and biotech do, and in 2026, that pace is accelerating rather than stabilizing. Several years removed from the pandemic, leaders are reassessing where capital truly creates value. AI is reshaping drug […]

Capex Confidential: Paper & Packaging

INSIDER PERSPECTIVES FOR CAPITAL INVESTMENT STAKEHOLDERS The paper and packaging industry is facing a moment of truth. While industry growth is now projected to increase from approximately $458.8 billion in 2025 to $583.9 billion globally by 2030 – a steady 4.9% annual growth rate (Mordor Intelligence, 2025) – it’s still a fraction of the explosive […]

2025 Was Challenging. Next Year May Be More So.

2025 Was Challenging. Next Year May Be More So. Be Prepared for Anything with a Capex Council. Let’s be honest: 2025 tested your capital allocation strategy in ways you probably couldn’t anticipate. And as you look ahead to 2026, many of the same variables persist: tariff uncertainty, technology disruption, supply chain headaches, and persistent inflation. […]

Five Industries Reshaping Capital Strategy in 2026

Webinar/Demo Series Roundup Five Industries Reshaping Capital Strategy in 2026 CAPITAL PLANNING | CAPEX BUDGETING | CAPEX MANAGEMENT Capital inefficiency. Outdated “static” approaches to budgeting and allocation. Processes that choke efficient decision-making and inhibit agility. These are some of the headwinds in today’s Capex landscape. Companies that do capital planning and management well have a significant […]

Essential Questions Facing Capex Stakeholders as We Approach 2026 and How to Answer Them

Essential Questions Facing Capex Stakeholders as We Approach 2026 … and How to Answer Them CAPITAL PLANNING | ROI MODELING | DIGITAL TRANSFORMATION As the dust settles on many organizations’ budgeting season, public policies come into clearer view (or not), and macroeconomics continue to be unpredictable, lingering questions remain for Capex stakeholders. In short, if […]

Underspending Capex: The Pitfalls of Leaving Capital Investment Dollars on the Table

Underspending Capex: The Pitfalls of Leaving Capital Investment Dollars on the Table UNDERSPENDING CAPEX | CAPEX BUDGET MANAGEMENT There’s no shortage of data and anecdotes describing the difficult decisions companies routinely have to make in determining which capital projects they can fund and those they cannot. Or of rampant overspending, which is more norm than […]

What Capex stakeholders need to know about the One Big Beautiful Bill Act

What do Capex stakeholders need to know about the One Big Beautiful Bill Act? CAPITAL PLANNING | CAPEX BUDGETING | OBBBA The One Big Beautiful Bill Act (OBBBA), signed July 4, 2025, isn’t just another tax tweak; it’s the biggest shift in capital planning rules since 2017. For Capex stakeholders, this is a critical time […]

Capex Confidential: Manufacturing

INSIDER PERSPECTIVES FOR CAPITAL INVESTMENT STAKEHOLDERS Large-scale investments in production lines, specialized machinery, automation, and infrastructure are paramount, effectively managing capital expenditures (Capex) – all of which have a bearing on market leadership … or stagnation., Because navigating these complex investments presents myriad challenges for financial executives and operations teams, staying abreast of best practices […]